<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01549119</url>
  </required_header>
  <id_info>
    <org_study_id>IVVAC-3S/P1</org_study_id>
    <nct_id>NCT01549119</nct_id>
  </id_info>
  <brief_title>Phase I/IIa Dose-escalation Clinical Study of VAC-3S</brief_title>
  <official_title>Multicentre, Randomized, Placebo-controlled, Double-blind, Phase I/IIa Dose-escalation Clinical Study of a Therapeutic Vaccine (VAC-3S) Intended to Confer Protection Against Immunopathological Effects of HIV-1 in Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InnaVirVax</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InnaVirVax</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the safety and immunogenicity of the therapeutic
      vaccine candidate VAC-3S in HIV-1 infected patients under AntiRetroviral Therapy (ART) with
      undetectable viral loads.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Study Participants Who Tolerated three vaccinations with VAC-3S at 4-weeks apart Determined by Safety Parameter Changes According to the DAIDS (Division of Acquired Immunodeficiency Syndrome) Adverse Events (AE) Grading Table.</measure>
    <time_frame>from D0 to week 24</time_frame>
    <description>Safety parameters include adverse events, vital signs, physical examinations, laboratory tests (hematology, blood chemistry, viral load).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-3S antibody titers</measure>
    <time_frame>from D0 to week 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Study Participants Who Tolerated three vaccinations with VAC-3S at 4-weeks apart Determined by Safety Parameter Changes According to the DAIDS (Division of Acquired Immunodeficiency Syndrome) Adverse Events (AE) Grading Table.</measure>
    <time_frame>from week 24 to week 60</time_frame>
    <description>Safety parameters include adverse events, vital signs, physical examinations, laboratory tests (hematology, blood chemistry, viral load).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NKp44L expression on the surface of CD4+ T lymphocytes</measure>
    <time_frame>from D0 to week 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of progression to AIDS. Markers include CD4+ cell count, viral load, and phenotypic markers of lymphocyte differentiation and activation.</measure>
    <time_frame>from D0 to week 60</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Low dose VAC-3S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose VAC-3S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose VAC-3S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Double-dose VAC-3S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VAC-3S</intervention_name>
    <description>Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL - 2 X 0.5 mL for double-dose arm 3 vaccinations at one month apart</description>
    <arm_group_label>Low dose VAC-3S</arm_group_label>
    <arm_group_label>Medium dose VAC-3S</arm_group_label>
    <arm_group_label>High dose VAC-3S</arm_group_label>
    <arm_group_label>Double-dose VAC-3S</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Comparison with experimental vaccine</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected patient

          -  Age between 18 and 55 years

          -  ART (AntiRetroviral Therapy) initiation 1 year ago

          -  Plasma HIV RNA below 50 copies per ml on three sequential occasions including V-1 in
             the past 12 months

          -  CD4 T cell count above or equal to 200 cells per mm3,

          -  Nadir CD4 T cell count above or equal to 100 cells per mm3,

          -  Contraception in women with child-bearing potential

        Exclusion Criteria:

          -  Any ART change within a month preceding screening.

          -  Chronic active liver disease, HIV-Hepatitis Coinfection.

          -  Immunotherapy in the past year, immunosuppressive treatment within the past month.

          -  History of auto-immune disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raphael Ho Tsong Fang, DVM, PHD</last_name>
    <role>Study Director</role>
    <affiliation>InnaVirVax</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIC Cochin Pasteur</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2012</study_first_submitted>
  <study_first_submitted_qc>March 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>January 30, 2015</last_update_submitted>
  <last_update_submitted_qc>January 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>HIV</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>active immunotherapy</keyword>
  <keyword>vaccine</keyword>
  <keyword>virulence</keyword>
  <keyword>innate immunity</keyword>
  <keyword>NK cells</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 24, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

